-
Archives
- December 2017
- June 2017
- May 2017
- February 2017
- November 2016
- October 2016
- September 2016
- July 2016
- April 2016
- March 2016
- December 2015
- August 2015
- April 2015
- February 2015
- January 2015
- December 2014
- November 2014
- September 2014
- August 2014
- July 2014
- May 2014
- January 2014
- December 2013
- November 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
-
Meta
Tag Archives: CMS
Medicare Case a Win For PatientsWith Chronic, Debilitating Conditions, Disabilities
Patients on Medicare with chronic conditions and disabilities will no longer have to show improvement to get skilled care and therapy services, according to a proposed settlement of a class action suit, Jimmo v. Sebelius. The settlement clarifies the standard … Continue reading
Inattention to Drug Safety in the Elderly
Leaves Generations At Risk
This post originally appeared in a slightly different form in Scientific American’s guest blog on June 30, 2011. My frail, 92-year-old mother was prescribed 80 mg of the cholesterol-lowering drug, or statin, simvastatin (Zocor) for years, possibly decades. She fell … Continue reading
Posted in aging, drug safety, falls
Tagged cholesterol, CMS, FDA, HEDIS, pay-for-performance, postmarketing surveillance, simvastatin
2 Comments